Table 2.

Grade ≥ 2 treatment related adverse events in ≥ 10% patients by cohort

	Cohort	A (n=40)			B (n=31)			B2 (n=33)			B3 (n=33)			C (n=22)
	Grade	2	3	4	2	3	4	2	3	4	2	3	4	2	3	4
AE (n, %) a
Amylase elevation		4 (10.0)	2 (5.0)	0	0	0	0	0	2 (6.1)	0	0	1 (3.0)	0	0	0	0
Fatigue		5 (12.5)	0	0	6 (19.4)	0	0	6 (18.2)	0	0	9 (27.3)	0	0	2 (9.1)	1 (4.5)	0
Headache		4 (10.0)	0	0	1 (3.2)	1 (3.2)	0	0	0	0	1 (3.0)	0	0	1 (4.5)	0	0
Hemiparesis		2 (5.0)	0	0	4 (12.9)	0	0	0	0	0	1 (3.0)	0	0	0	0	0
Hypertension		0	0	0	1 (3.2)	0	0	1 (3.0)	4 (12.1)	0	2 (6.1)	0	0	1 (4.5)	0	0
Lipase elevation		3 (7.5)	5 (12.5)	1 (2.5)	0	0	1 (3.2)	1 (3.0)	0	0	0	3 (9.1)	0	0	0	0

^aPercents are per cohort